Abstract 249P
Background
Abnormal uterine bleeding is the most common complaint in women attending to physicians, especially in the peri-menopausal and post-menopausal period which is reported to account for 70% of all gynecological consultations. The main aim of investigations for abnormal uterine bleeding is to rule out intrauterine pathology, particularly endometrial cancer or atypical hyperplasia.The study was aimed to conduct a systematic review and meta-analysis to evaluate the diagnostic accuracy of endometrial biopsy with Pipelle in women with abnormal uterine bleeding compared to D&C (reference standard) and sufficiency of the obtained endometrial tissue of two techniques.
Methods
Literature for studies published between 1965 and 2019 comparing the results of Pipelle with findings by D&C was searched. The QUADAS 2 tool was performed to evaluate the risk and applicability of each study. The diagnostic accuracy of Pipelle was evaluated through calculation of sensitivity, specificity, positive likelihood ratio, negative likelihood ratio and diagnostic odds ratio with pooled proportion.
Results
A total of 8 studies and 1675 patients were included in this meta-analysis. The pooled sensitivity of endometrial sampling by Pipelle was 70.9% (95%CI: 58.1%-81.1%) in endometrial tumor, 97.2% (95%CI: 95.5%-98.3%) in endometrial benign disease, and 94.4% (95%CI 92.7%-95.8%) in normal endometrium. The pooled specificity of Pipelle was 99.6% (95%CI: 99.0%-99.9%) in endometrial tumor, 74.7% (95% 56.4%-87.1%) in endometrial benign disease, and 90.0% (95%CI 75.5%-96.3%) in normal endometrium. The positive likelihood ratio by Pipelle in the diagnosis of endometrial tumor, benign disease and normal endometrium was 191.06 (95%CI 70.81-515.48), 28.86 (95%CI 15.10-55.19) and 9.573 (95%CI 4.28-21.40), while the negative likelihood ratio by Pipelle was 0.337 (95%CI 0.236-0.482), 0.241 (95%CI 0.131-0.444) and 0.07 (95%CI 0.04-0.11), respectively. The highest DOR 851.68 was achieved in the result of endometrial tumor.
Conclusions
Pipelle can be introduced as a suitable alternative of diagnostic curettage. When an adequate specimen is obtained, a positive test result is more accurate for ruling in disease than a negative test result for ruling it out.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
107P - The efficacy of adjuvant chemotherapy according to the risk classification of recurrence based on the systemic inflammatory markers in patients with colorectal cancer liver metastases
Presenter: Masatsune Shibutani
Session: Poster display session
Resources:
Abstract
108P - Influence of liver metastasis locations on overall survival in patients with colorectal cancer
Presenter: Takayuki Sone
Session: Poster display session
Resources:
Abstract
109P - 18F-FDG PET/CT textural features as predictors of outcomes in patients with primary advanced colorectal cancer
Presenter: Jing Yang
Session: Poster display session
Resources:
Abstract
110P - D3 lymph node dissection may be necessary in clinical stage I right colon cancer
Presenter: Woong Bae Ji
Session: Poster display session
Resources:
Abstract
111P - Is preoperative chemoradiotherapy necessary for all patients with upper rectal cancer: One center retrospective study
Presenter: Jasur Madyarov
Session: Poster display session
Resources:
Abstract
112P - A retrospective analysis of the association between perioperative, post adjuvant carcinoembryonic antigen level and prognosis in stage III colorectal cancer
Presenter: Ryotaro Kozuki
Session: Poster display session
Resources:
Abstract
113P - Dicer contributes to chemoresistance in colorectal cancer via regulating a set of miRNAs and their downstream mRNAs
Presenter: Liang-Yi Hung
Session: Poster display session
Resources:
Abstract
114P - Efficacy and safety of the combination of bevacizumab with raltitrexed-based chemotherapy as second-line therapy in patients with metastatic colorectal cancer (mCRC): An interim analysis of a multicenter phase II trial
Presenter: Jun Zhu
Session: Poster display session
Resources:
Abstract
115P - Expression of Ki-67 as a prognostic factor in patients with colorectal cancer
Presenter: Kuantkan Zhabagin
Session: Poster display session
Resources:
Abstract
116P - Clinical significance and converionrate relevance of RAS genetic mutation analysis for unresectable colorectal liver metastases: A single-center retrospective study
Presenter: Meiling Ji
Session: Poster display session
Resources:
Abstract